KR20150080007A - 겔로부터 콤스타틴 유사체의 지속적 운반 - Google Patents

겔로부터 콤스타틴 유사체의 지속적 운반 Download PDF

Info

Publication number
KR20150080007A
KR20150080007A KR1020157016589A KR20157016589A KR20150080007A KR 20150080007 A KR20150080007 A KR 20150080007A KR 1020157016589 A KR1020157016589 A KR 1020157016589A KR 20157016589 A KR20157016589 A KR 20157016589A KR 20150080007 A KR20150080007 A KR 20150080007A
Authority
KR
South Korea
Prior art keywords
analog
comstatin
gel
trp
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157016589A
Other languages
English (en)
Korean (ko)
Inventor
세드릭 프랑수와
파스칼 데스차텔레츠
폴 올슨
Original Assignee
포텐시아 팔마큐티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포텐시아 팔마큐티칼스, 인크. filed Critical 포텐시아 팔마큐티칼스, 인크.
Publication of KR20150080007A publication Critical patent/KR20150080007A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157016589A 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반 Ceased KR20150080007A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107008703A Division KR20100094453A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Publications (1)

Publication Number Publication Date
KR20150080007A true KR20150080007A (ko) 2015-07-08

Family

ID=40526950

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157016589A Ceased KR20150080007A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반
KR1020107008703A Ceased KR20100094453A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107008703A Ceased KR20100094453A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Country Status (12)

Country Link
US (1) US20110182877A1 (cg-RX-API-DMAC7.html)
EP (1) EP2207530A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010540654A (cg-RX-API-DMAC7.html)
KR (2) KR20150080007A (cg-RX-API-DMAC7.html)
CN (1) CN101854916A (cg-RX-API-DMAC7.html)
AU (1) AU2008308657A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817524A2 (cg-RX-API-DMAC7.html)
CA (1) CA2701470A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010003630A (cg-RX-API-DMAC7.html)
RU (1) RU2505311C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009046198A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002365B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
NZ607103A (en) 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
EP2425814B1 (en) 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
SMT202100688T1 (it) 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
KR20260070290A (ko) 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
BR112019020955A2 (pt) 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 投与レジメンならびに関連組成物および方法
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7989589B2 (en) * 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101325963B (zh) * 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
JP2009521506A (ja) * 2005-12-22 2009-06-04 アルコン リサーチ, リミテッド 補体因子hの危険である改変体をもつ患者における年齢による斑状変性の予防および処置のためのc3コンバターゼインヒビター
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
EP2148691B1 (en) * 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system

Also Published As

Publication number Publication date
WO2009046198A3 (en) 2009-07-16
CN101854916A (zh) 2010-10-06
ZA201002365B (en) 2010-12-29
JP2010540654A (ja) 2010-12-24
RU2505311C2 (ru) 2014-01-27
EP2207530A2 (en) 2010-07-21
BRPI0817524A2 (pt) 2017-05-02
WO2009046198A2 (en) 2009-04-09
CA2701470A1 (en) 2009-04-09
MX2010003630A (es) 2010-04-21
US20110182877A1 (en) 2011-07-28
RU2010113513A (ru) 2011-11-10
EP2207530A4 (en) 2013-09-11
KR20100094453A (ko) 2010-08-26
AU2008308657A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
RU2505311C2 (ru) Пролонгированная доставка аналогов компстатина из гелей
JP6305382B2 (ja) 眼の障害のためのコンプスタチンおよびそのアナログ
US10407466B2 (en) Methods of selecting compstatin mimetics
JP2023027172A (ja) ノリン誘発性の遺伝子発現および疾患を処置するためのその使用
AU2016253654A1 (en) Injectable combination therapy for eye disorders
WO2022061304A1 (en) Methods of treating eye disorders
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares
HK1121380B (en) Compstatin and analogs thereof for eye disorders
HK1121380A (en) Compstatin and analogs thereof for eye disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150622

Application number text: 1020107008703

Filing date: 20100421

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150721

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151008

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160719

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151008

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I